News & Press

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases
Abbisko Therapeutics Completes Dosing of the First Subject in the Dose Expansion Part of Phase I Trial for CSF-1R Inhibitor ABSK021
Nov 17, 2021
Abbisko’s Partner X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
Nov 03, 2021
Abbisko Therapeutics R&D and Manufacturing Facility Landed in Zhangjiang
Oct 29, 2021
Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK061, A Selective Inhibitor of FGFR2 and FGFR3, by the U.S. FDA
Oct 25, 2021
Abbisko Therapeutics Announces the IND Approval by NMPA for Phase II Clinical Trial of ABSK011
Oct 19, 2021
Abbisko Cayman Limited successfully landed on the Hong Kong Stock Exchange
Oct 15, 2021
View all
we discover and develop first-in-class and best-in-class therapies
to address critical unmet needs for cancer patients in China and globally
Media
Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA
Dec 14, 2020
Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome
Jun 19, 2020
Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011
Apr 07, 2020
Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547
Nov 08, 2019
View all

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1